SR One

SR One investment thesis

Team Portfolio News Contact We are SR One Our Mission Transatlantic SR One A biotechnology venture capital firm, partnering with founders and entrepreneurs to translate innovative science into medicines. Meet the Team Scroll to discover more We are on a mission to power the arc of innovation from science to medicine SR One takes a back-and-build approach to its investments. Focusing on companies that we believe have strong underlying fundamentals, a clearly defined development pathway, and novel approaches to addressing diseases, SR One aims to help reimagine today’s science for tomorrow’s medicines. Discover our Portfolio dren-logo-white pulmocide-white-logo Group Our transatlantic presence allows us to access high quality science and opportunities across geographies SR One’s investing te

SR One team (12)

Partners and principals at SR One:

• Heather Behanna — sweet spot $2.8M
• Chris Chai — sweet spot $2.8M
• Eliot Charles — sweet spot $2.8M
• Rodger Novak — sweet spot $2.8M
• Amit Shah — sweet spot $2.8M
• Peter Van Vlasselaer, PhD — sweet spot $2.8M
• Jill carroll — sweet spot $2.8M
• Rajeev Dadoo — sweet spot $2.8M
• Matthew Foy — sweet spot $2.8M
• Simeon J. George — sweet spot $2.8M
• Vikas Goyal — sweet spot $2.8M
• Deborah Harland — sweet spot $2.8M

SR One portfolio companies

Companies listed on SR One's public materials include: Team, Portfolio, News, All, Private, Public, Exited, Active, Clinical, Preclinical, Cardiometabolic, CNS, Immunology, Infectious Disease, Oncology, Rare diseases, Renal, Other, Neuropsychiatry, Hematology, Rheumatology, Multiple, LinkedIn, sronemedia@sambrown.com, Regulatory Disclosures, Back to Portfolio, dren-logo Dren Bio, Website, Rajeev Dadoo, PhD, Previous, Next.

Is SR One a fit for your round?

Upload your pitch deck and see whether anyone at SR One appears in your top matches.